The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide ...

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a ...

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...